DK1727795T3 - Fremgangsmåde til fremstillingen af atorvastatin-calcium i amorf form - Google Patents
Fremgangsmåde til fremstillingen af atorvastatin-calcium i amorf formInfo
- Publication number
- DK1727795T3 DK1727795T3 DK04798913.2T DK04798913T DK1727795T3 DK 1727795 T3 DK1727795 T3 DK 1727795T3 DK 04798913 T DK04798913 T DK 04798913T DK 1727795 T3 DK1727795 T3 DK 1727795T3
- Authority
- DK
- Denmark
- Prior art keywords
- amorf
- procedure
- preparation
- atorvastatin calcium
- atorvastatin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN491DE2004 | 2004-03-17 | ||
PCT/IB2004/003789 WO2005092852A1 (en) | 2004-03-17 | 2004-11-19 | Process for the production of atorvastatin calcium in amorphous form |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1727795T3 true DK1727795T3 (da) | 2012-04-16 |
Family
ID=33516010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04798913.2T DK1727795T3 (da) | 2004-03-17 | 2004-11-19 | Fremgangsmåde til fremstillingen af atorvastatin-calcium i amorf form |
Country Status (17)
Country | Link |
---|---|
US (1) | US7994343B2 (da) |
EP (3) | EP1727795B1 (da) |
CN (2) | CN1942439B (da) |
AR (1) | AR048271A1 (da) |
AT (1) | ATE545629T1 (da) |
AU (2) | AU2004317570B2 (da) |
CA (3) | CA2560252C (da) |
CY (1) | CY1112583T1 (da) |
DK (1) | DK1727795T3 (da) |
ES (1) | ES2381473T3 (da) |
FI (1) | FI120344B (da) |
MY (1) | MY147435A (da) |
NO (1) | NO330092B1 (da) |
PL (1) | PL1727795T3 (da) |
PT (1) | PT1727795E (da) |
SI (1) | SI1727795T1 (da) |
WO (1) | WO2005092852A1 (da) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2381473T3 (es) * | 2004-03-17 | 2012-05-28 | Ranbaxy Laboratories Limited | Procedimiento para la preparación de atorvastatina cálcica en forma amorfa |
EP1771455B1 (en) * | 2004-07-16 | 2016-05-11 | LEK Pharmaceuticals d.d. | Oxidative degradation products of atorvastatin calcium |
CA2578722C (en) * | 2004-08-27 | 2010-02-02 | Biocon Limited | Process for atorvastatin calcium amorphous |
GB2424880A (en) * | 2005-04-06 | 2006-10-11 | Generics | Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase |
BRPI0614280A2 (pt) | 2005-08-15 | 2009-08-04 | Arrow Int Ltd | atorvastatina sódica cristalina e amorfa |
GB0613566D0 (en) * | 2006-07-07 | 2006-08-16 | Arrow Int Ltd | Crystalline sodium atorvastatin |
GB0613567D0 (en) * | 2006-07-07 | 2006-08-16 | Arrow Int Ltd | Crystalline sodium atorvastatin |
CA2619486C (en) | 2005-08-15 | 2015-05-12 | Arrow International Limited | Crystalline and amorphous sodium atorvastatin |
ES2270722B1 (es) * | 2005-09-15 | 2008-03-01 | Ercros Industrial, S.A. | Procedimiento para la obtencion de atorvastatina calcica amorfa. |
GB0523637D0 (en) * | 2005-11-21 | 2005-12-28 | Avecia Pharmaceuticals Ltd | Process and compounds |
WO2007099552A2 (en) * | 2006-03-02 | 2007-09-07 | Matrix Labaratories Ltd | Novel crystalline form of atovastatin hemi-magnesium |
SI22255A (sl) * | 2006-04-14 | 2007-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah |
CN101205209B (zh) * | 2007-12-25 | 2010-06-02 | 浙江新东港药业股份有限公司 | 一种阿伐他汀中间体的精制方法 |
EP2075246A1 (en) * | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
CN101468963B (zh) * | 2007-12-28 | 2012-09-19 | 石药集团中奇制药技术(石家庄)有限公司 | 一种无定形阿伐他汀钙的制备方法 |
KR100850558B1 (ko) * | 2008-01-02 | 2008-08-06 | 조동옥 | 아토르바스타틴의 효율적인 제조방법 |
CN101560177B (zh) * | 2008-04-16 | 2012-10-03 | 北京万全阳光医学技术有限公司 | 一种阿托伐他汀钙的制备方法 |
CN101429195B (zh) * | 2008-11-03 | 2010-12-15 | 华东师范大学 | 一种高纯度阿托伐他汀重要合成中间体的制备方法 |
US8115015B2 (en) | 2009-01-26 | 2012-02-14 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
US20130041162A1 (en) * | 2010-04-19 | 2013-02-14 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Production of atorvastatin low in ether impurities |
CN102127060B (zh) * | 2010-12-17 | 2013-12-04 | 蚌埠丰原医药科技发展有限公司 | 一种阿托伐他汀钙中间体的制备方法 |
CN102070504A (zh) * | 2010-12-23 | 2011-05-25 | 蚌埠丰原医药科技发展有限公司 | 阿托伐他汀钠的制备方法 |
CN102070505B (zh) * | 2011-01-28 | 2012-01-11 | 海南美大制药有限公司 | 阿托伐他汀钙化合物及其新制法 |
CN103483238B (zh) * | 2013-08-20 | 2014-12-31 | 蚌埠丰原医药科技发展有限公司 | 阿托伐他汀钙三水合物的制备方法 |
CN104945300B (zh) * | 2015-06-17 | 2017-05-10 | 北京嘉林药业股份有限公司 | 一种ⅰ型阿托伐他汀钙的纯化方法 |
WO2017060885A1 (en) * | 2015-10-09 | 2017-04-13 | Laurus Labs Private Limited | An improved process for preparation of atorvastatin or pharmaceutically acceptable salts thereof |
CN106478591B (zh) * | 2016-09-30 | 2018-11-13 | 北京嘉林药业股份有限公司 | 一种阿托伐他汀缩合物中间体的拆分方法 |
CN106432033B (zh) * | 2016-10-21 | 2018-07-27 | 江苏阿尔法药业有限公司 | 一种无定形阿托伐他汀钙的制备方法 |
CN108033899B (zh) * | 2017-12-06 | 2020-04-10 | 浙江科技学院 | 一种(r)-6-氰基-5-羟基-3-羰基己酸叔丁酯的制备方法 |
CN109280024A (zh) * | 2018-10-09 | 2019-01-29 | 河南师范大学 | 一种高纯度阿托伐他汀叔丁酯的制备方法 |
CN109232355A (zh) * | 2018-10-09 | 2019-01-18 | 河南师范大学 | 一种有效去除阿托伐他汀钙粗品中杂质阿托伐他汀缩合物的方法 |
CN110563628B (zh) * | 2019-08-26 | 2022-04-05 | 北京嘉林药业股份有限公司 | 一种双釜制备高纯度和单分散i晶型阿托伐他汀钙的结晶方法 |
CN110776451B (zh) * | 2020-01-02 | 2020-05-22 | 湖南迪诺制药股份有限公司 | 一种i晶型阿托伐他汀钙的制备方法 |
CN113695307B (zh) * | 2020-05-20 | 2022-12-02 | 天津嘉林科医有限公司 | 一种盛放阿托伐他汀钙的玻璃器皿的清洗方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
ATE178794T1 (de) | 1993-01-19 | 1999-04-15 | Warner Lambert Co | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
BR9609872A (pt) | 1995-07-17 | 1999-03-23 | Warner Lambert Co | Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino |
IN191236B (da) | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
US6646133B1 (en) * | 2000-10-17 | 2003-11-11 | Egis Gyogyszergyar Rt. | Process for the preparation of amorphous atorvastatin calcium |
HU226640B1 (en) | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
SI20425A (sl) | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
SK16982002A3 (sk) | 2000-06-09 | 2003-04-01 | Lek Pharmaceuticals D. D. | Stabilizovaná farmaceuticky účinná kompozícia a liečivý prípravok túto kompozíciu obsahujúci |
CN1535139A (zh) | 2000-11-03 | 2004-10-06 | ������ҩ��ҵ����˾ | 阿伐他丁半钙形式ⅶ |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
WO2002057225A2 (en) | 2000-12-18 | 2002-07-25 | Merck & Co., Inc. | Thrombin inhibitors |
MXPA03005879A (es) | 2000-12-27 | 2003-09-10 | Ciba Sc Holding Ag | Formas cristalinas de atorvastatina. |
WO2002057228A1 (en) | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
IN190564B (da) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
AP1571A (en) | 2001-06-29 | 2006-02-10 | Warner Lambert Co | Crystalline forms of 'R-(R* ,R*)!-2-(4- fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
AU2002255479B2 (en) | 2001-07-30 | 2008-09-11 | Dr. Reddy's Laboratories Ltd. | Crystalline forms VI and VII of atorvastatin clacium |
EP1572638A4 (en) | 2001-08-31 | 2010-05-05 | Morepen Lab Ltd | IMPROVED PROCESS FOR THE PREPARATION OF AMORPHOUS CALCIUM ATORVASTATIN SALT (2: 1) |
CZ296967B6 (cs) * | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
BR0215644A (pt) | 2002-03-18 | 2004-12-21 | Biocon Ltd | Inibidores de redutase de hmg-coa amorfos do tamanho de partìcula desejado |
WO2003099785A1 (en) | 2002-05-28 | 2003-12-04 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
SI21302A (sl) | 2002-10-11 | 2004-04-30 | LEK farmacevtska dru�ba d.d. | Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino |
HU227041B1 (en) | 2003-03-24 | 2010-05-28 | Richter Gedeon Nyrt | Process for the synthesis of amorphous atorvastatin calcium |
ES2381473T3 (es) * | 2004-03-17 | 2012-05-28 | Ranbaxy Laboratories Limited | Procedimiento para la preparación de atorvastatina cálcica en forma amorfa |
ES2263407T1 (es) | 2004-09-28 | 2006-12-16 | Teva Pharmaceutical Industries Ltd | Procedimiento para la preparacion de formas de atorvastatina calcica sustancialmente libres de impurezas. |
-
2004
- 2004-11-19 ES ES04798913T patent/ES2381473T3/es active Active
- 2004-11-19 SI SI200431843T patent/SI1727795T1/sl unknown
- 2004-11-19 AT AT04798913T patent/ATE545629T1/de active
- 2004-11-19 PT PT04798913T patent/PT1727795E/pt unknown
- 2004-11-19 AU AU2004317570A patent/AU2004317570B2/en not_active Ceased
- 2004-11-19 CA CA002560252A patent/CA2560252C/en not_active Expired - Fee Related
- 2004-11-19 CA CA002666359A patent/CA2666359A1/en not_active Abandoned
- 2004-11-19 DK DK04798913.2T patent/DK1727795T3/da active
- 2004-11-19 NO NO20045037A patent/NO330092B1/no not_active IP Right Cessation
- 2004-11-19 PL PL04798913T patent/PL1727795T3/pl unknown
- 2004-11-19 US US10/549,890 patent/US7994343B2/en not_active Expired - Fee Related
- 2004-11-19 WO PCT/IB2004/003789 patent/WO2005092852A1/en active Application Filing
- 2004-11-19 CA CA002627940A patent/CA2627940A1/en not_active Abandoned
- 2004-11-19 CN CN2004800428343A patent/CN1942439B/zh not_active Expired - Fee Related
- 2004-11-19 FI FI20041489A patent/FI120344B/fi not_active IP Right Cessation
- 2004-11-19 EP EP04798913A patent/EP1727795B1/en active Active
- 2004-11-19 EP EP04027584A patent/EP1577297A1/en not_active Withdrawn
-
2005
- 2005-03-16 AR ARP050101018A patent/AR048271A1/es unknown
- 2005-03-17 CN CNA200580012704XA patent/CN1946688A/zh active Pending
- 2005-03-17 MY MYPI20051161A patent/MY147435A/en unknown
- 2005-09-16 EP EP05077109A patent/EP1659110A1/en not_active Ceased
-
2010
- 2010-12-03 AU AU2010249166A patent/AU2010249166B2/en not_active Ceased
-
2012
- 2012-04-04 CY CY20121100335T patent/CY1112583T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN1942439B (zh) | 2011-12-21 |
NO20045037L (no) | 2005-09-19 |
CA2560252A1 (en) | 2005-10-06 |
EP1727795A1 (en) | 2006-12-06 |
WO2005092852A1 (en) | 2005-10-06 |
CA2666359A1 (en) | 2005-10-06 |
PT1727795E (pt) | 2012-04-11 |
AU2010249166A1 (en) | 2010-12-23 |
ATE545629T1 (de) | 2012-03-15 |
AU2004317570B2 (en) | 2011-01-06 |
MY147435A (en) | 2012-12-14 |
EP1659110A1 (en) | 2006-05-24 |
US7994343B2 (en) | 2011-08-09 |
PL1727795T3 (pl) | 2012-06-29 |
FI20041489A0 (fi) | 2004-11-19 |
NO20045037D0 (no) | 2004-11-19 |
SI1727795T1 (sl) | 2012-05-31 |
AU2010249166B2 (en) | 2012-02-09 |
CA2627940A1 (en) | 2005-10-06 |
AR048271A1 (es) | 2006-04-12 |
CY1112583T1 (el) | 2016-02-10 |
ES2381473T3 (es) | 2012-05-28 |
EP1727795B1 (en) | 2012-02-15 |
NO330092B1 (no) | 2011-02-14 |
CA2560252C (en) | 2009-08-04 |
US20100197941A1 (en) | 2010-08-05 |
AU2004317570A1 (en) | 2005-10-06 |
EP1577297A1 (en) | 2005-09-21 |
CN1942439A (zh) | 2007-04-04 |
CN1946688A (zh) | 2007-04-11 |
FI20041489A (fi) | 2006-07-20 |
FI120344B (fi) | 2009-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1727795T3 (da) | Fremgangsmåde til fremstillingen af atorvastatin-calcium i amorf form | |
DK1828164T3 (da) | Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider | |
DK1778668T3 (da) | Fremgangsmåde til fremstilling af dihydropteridion | |
DK2141204T3 (da) | Fremgangsmåde til fremstilling af bituminøse sammensætninger | |
DK1830956T3 (da) | Fremgangsmåde til forberedelse af katalytiske materialer | |
DK1748077T3 (da) | Fremgangsmåde til fremstilling af protein | |
DK1893586T3 (da) | Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler | |
DK2929891T3 (da) | Fremgangsmåde til modulering af appetitten | |
DK1877232T3 (da) | Fremgangsmåde til behandling af træoverflader | |
DK1805312T3 (da) | Fremgangsmåder og midler til fremstilling af hyaluronan | |
DE602005009729D1 (de) | System zur zubereitung von getränken | |
DK1957656T3 (da) | Fermentativ fremstilling af lysin | |
DE502005000881D1 (de) | Knochenverankerungselement | |
FI20041059A0 (fi) | Komponentin sisältävän kerroksen valmistaminen | |
DK1852430T3 (da) | Fremgangsmåde til fremstilling af proanthocyanidinoligomer | |
DK1948176T3 (da) | Diarylurinstoffer til behandling af pulmonær hypertension | |
DK1827412T3 (da) | Sammensætninger til anvendelse i kirurgi | |
DK1922309T3 (da) | N-phenyl-2-pyrimidin-aminderivater og fremgangsmåde til fremstillingen deraf | |
DK1612200T3 (da) | Gødningssammensætning | |
DE602005017191D1 (de) | Geruchsreduzierte waschstück-zusammensetzung | |
DK1831223T3 (da) | Fremgangsmåde til fremstilling af L-biopterin | |
NO20043305D0 (no) | Preparation of lodixanol | |
DK1856035T3 (da) | Fremgangsmåde til fremstilling af beskyttelse amidiner | |
DK2390326T3 (da) | Fremgangsmåde til fremstilling af et humant type II-collagen | |
DK1912961T3 (da) | Fremgangsmåde til fremstilling af bepromolin |